64 results
8-K
LTRN
Lantern Pharma Inc
24 Nov 23
Entry into a Material Definitive Agreement
4:05pm
) was for the purpose of generating working capital for the operations of the Bios Entities and ensuring adequate liquidity.
SIGNATURES
Pursuant
S-3
x3r8ooliowya474
2 Jul 21
Shelf registration
4:15pm
S-3
EX-4.3
0lcir5zwr3
2 Jul 21
Shelf registration
4:15pm
S-3
EX-4.2
g3x81ymbj2a
2 Jul 21
Shelf registration
4:15pm
DEF 14A
njl4m 1be9b96a
9 Apr 21
Definitive proxy
11:30am
10-K
d0ijwyh3pa5
10 Mar 21
Annual report
4:07pm
10-K
EX-32.1
9g2g701h9z0k
10 Mar 21
Annual report
4:07pm
424B4
5e1kr3mqjjf0o
15 Jan 21
Prospectus supplement with pricing info
5:24pm
S-1MEF
l7j6aix warp9k6
15 Jan 21
Registration of additional securities for an S-1
6:03am